Nuvation Bio Inc.

NYSE NUVB

Nuvation Bio Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 104.09 M

Nuvation Bio Inc. Net Cash Used For Investing Activities is USD 104.09 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 325.94% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Nuvation Bio Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -46.07 M, a 55.69% change year over year.
Nuvation Bio Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -103.98 M, a 71.41% change year over year.
Nuvation Bio Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -363.67 M, a -1,401.04% change year over year.
Nuvation Bio Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 27.95 M.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NYSE: NUVB

Nuvation Bio Inc.

CEO	Dr. David T. Hung M.D.
IPO Date	Aug. 26, 2020
Location	United States
Headquarters	1500 Broadway
Employees	203
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Key trends

Past 5 years